Valuation : Alvotech

Market Cap 1.77B 1.52B 1.43B 1.3B 2.45B 169B 2.46B 16.93B 6.61B 85.24B 6.63B 6.49B 283B P/E 2026 *
95.2x
P/E 2027 * 16.7x
Enterprise Value 2.88B 2.48B 2.32B 2.12B 4B 275B 4.01B 27.58B 10.76B 139B 10.8B 10.57B 460B EV / Sales 2026 *
4.36x
EV / Sales 2027 * 3.67x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day+1.43%
1 week+11.74%
Current month+20.15%
1 month+59.68%
3 months+44.31%
6 months+24.06%
Current year-3.51%
1 week 4.72
Extreme 4.715
5.39
1 month 3.49
Extreme 3.49
5.39
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.25
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
1/4/26 Free

Chief Executive Officer

117,271 0.0355%
1/4/26 Sell

Founder

318,000 0.0963%
1/4/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+1.43%+11.74%-38.51%-48.97% 1.77B
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.24%-1.52%+66.83%+97.01% 27.63B
Weighted average by Cap. -1.68%-1.09%+94.80%+132.39%

Financials

2026 *2027 *
Net sales 659M 568M 533M 486M 916M 63.01B 919M 6.32B 2.47B 31.81B 2.48B 2.42B 105B 776M 668M 627M 572M 1.08B 74.14B 1.08B 7.44B 2.9B 37.42B 2.91B 2.85B 124B
Net income 30.36M 26.16M 24.53M 22.39M 42.18M 2.9B 42.32M 291M 114M 1.46B 114M 112M 4.86B 109M 94.02M 88.15M 80.47M 152M 10.43B 152M 1.05B 408M 5.26B 410M 401M 17.45B
Net Debt 1.11B 957M 897M 819M 1.54B 106B 1.55B 10.65B 4.15B 53.58B 4.17B 4.08B 178B 1.08B 933M 875M 799M 1.5B 104B 1.51B 10.38B 4.05B 52.26B 4.07B 3.98B 173B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
28/08/26 USD 4.950 +1.43% 878,430
27/08/26 USD 4.880 -0.61% 967,686
26/08/26 USD 4.910 -2.77% 890,179
25/08/26 USD 5.050 -3.81% 1,771,959
24/08/26 USD 5.250 +18.51% 3,178,120
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.950USD
Average target price
6.000USD
Spread / Average Target
+21.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock